Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32,333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptor.
Jung HH, Park YH, Jun HJ, Kong J, Kim JH, Kim JA, Yun J, Sun JM, Won YW, Lee S, Kim ST, Ahn JS, Im YH. Jung HH, et al. Among authors: kim st, kim ja, kim jh. Mol Cancer Res. 2010 Jul;8(7):1037-47. doi: 10.1158/1541-7786.MCR-09-0469. Epub 2010 Jun 15. Mol Cancer Res. 2010. PMID: 20551150
High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients.
Cho SY, Park C, Na D, Han JY, Lee J, Park OK, Zhang C, Sung CO, Moon HE, Kim Y, Kim JH, Kim JJ, Khang SK, Nam DH, Choi JW, Suh YL, Kim DG, Park SH, Youn H, Yun K, Kim JI, Lee C, Paek SH, Park H. Cho SY, et al. Among authors: kim ji, kim jj, kim dg, kim y, kim jh. Exp Mol Med. 2017 Apr 14;49(4):e317. doi: 10.1038/emm.2017.9. Exp Mol Med. 2017. PMID: 28408749 Free PMC article.
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).
Ahn GS, Hwang K, Kim TM, Park CK, Chang JH, Jung TY, Kim JH, Nam DH, Kim SH, Yoo H, Hong YK, Kim EY, Lee DE, Joo J, Kim YJ, Choe G, Choi BS, Kang SG, Kim JH, Kim CY. Ahn GS, et al. Among authors: kim yj, kim ey, kim sh, kim cy, kim tm, kim jh. Cancer Res Treat. 2022 Apr;54(2):396-405. doi: 10.4143/crt.2021.393. Epub 2021 Jul 6. Cancer Res Treat. 2022. PMID: 34237210 Free PMC article. Clinical Trial.
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, Kim JH, Cho YH, Yoon SM, Chang JH, Kang SG, Kim EH, Suh CO, Jung TY, Lee KH, Kim CY, Kim IA, Hong CK, Yoo H, Kim JH, Kang SH, Kang MK, Kim EY, Kim SH, Chung DS, Hwang SC, Song JH, Cho SJ, Lee SI, Lee YS, Ahn KJ, Kim SH, Lim DH, Gwak HS, Lee SH, Hong YK. Kim BS, et al. Among authors: kim ih, kim eh, kim ey, kim sh, kim cy, kim ia, kim tm, kim jh. Cancer Res Treat. 2017 Jan;49(1):193-203. doi: 10.4143/crt.2015.473. Epub 2016 Jun 27. Cancer Res Treat. 2017. PMID: 27384161 Free PMC article.
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
Hwang K, Kim TM, Park CK, Chang JH, Jung TY, Kim JH, Nam DH, Kim SH, Yoo H, Hong YK, Kim EY, Lee DE, Joo J, Kim YJ, Choe G, Choi BS, Kang SG, Kim JH, Kim CY. Hwang K, et al. Among authors: kim yj, kim ey, kim sh, kim cy, kim tm, kim jh. Cancer Res Treat. 2020 Apr;52(2):505-515. doi: 10.4143/crt.2019.421. Epub 2019 Oct 28. Cancer Res Treat. 2020. PMID: 31671938 Free PMC article. Clinical Trial.
32,333 results
You have reached the last available page of results. Please see the User Guide for more information.